Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Gynecologic Cancer Clinical Trial

Official title: An Open Label Post-Trial Access (PTA) of Catequentinib (AL3818, Anlotinib) Hydrochloride Mono or in Combination Therapies in Patients Who Have Completed an Advenchen Sponsored Oncology Study With AL3818 (A Compassionate Use Trial)

Status Available

Clinical Trial Summary

Catequentinib (AL3818, Anlotinib) has been developed in a variety of clinical studies as single agents or in combination with others. This trial is designed to offer patients who completed an Advenchen sponsored AL3818 related study without progression the opportunity to continue to receive this investigational product in this Post-Trial Access study (a compassionate use trial), if the Investigator believes the patients can benefit from such a treatment and the patients have signed the Informed Consent Form.

Clinical Trial Description

This is an open label trial and is designed to offer patients who are in a completed Advenchen sponsored AL3818 study without progression the opportunity to continue to receive AL3818. Qualified patients will continue therapy on their regimen established in the approved parent AL3818 clinical study until disease progression, physician decision, patient withdrawal, or sponsor discontinuation of the study. Dose modifications will be based on the suggestions in the approved parent AL3818 clinical study. Patients may be required to come to the site to receive AL3818. For patients who cannot come to the site to receive AL3818, the Site may mail the drug to the patient. The exact dispersing methods will be based on the Investigator's discretion. ;

Related Conditions & MeSH terms

• Gynecologic Cancer
• Sarcoma
• Sarcoma,Soft Tissue

• NCT number: NCT05612191
• Study type: Expanded Access
• Source: Advenchen Laboratories, LLC
• Contact: Judy Chen
• Phone: 8055301550
• Email: info@advenchen.com
• Status: Available